Tetraphase Pharmaceuticals Upgraded to Hold by TheStreet (TTPH)
The analysts wrote, “Tetraphase Pharmaceuticals (TTPH) has been upgraded by TheStreet Ratings from sell to hold. The company’s strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company’s earnings per share, deteriorating net income and weak operating cash flow.”
Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up 6.47% during mid-day trading on Friday, hitting $13.83. 416,951 shares of the company’s stock traded hands. Tetraphase Pharmaceuticals has a 1-year low of $7.02 and a 1-year high of $17.74. The stock has a 50-day moving average of $10.31 and a 200-day moving average of $12.24. The company’s market cap is $357.3 million.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings data on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.08. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.97 million. Analysts expect that Tetraphase Pharmaceuticals will post $-2.07 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Gabelli initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Friday. They set a “buy” rating on the stock. Separately, analysts at Robert W. Baird initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Monday. They set an “outperform” rating and a $21.00 price target on the stock. Finally, analysts at WBB Securities upgraded shares of Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating in a research note on Monday, June 2nd. They now have a $16.00 price target on the stock, up previously from $13.50. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $18.75.
In other Tetraphase Pharmaceuticals news, Insider Guy Macdonald sold 15,000 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $12.28, for a total value of $184,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.